ReviewNature reviews. Cancer2010
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.
Review in Nature reviews. Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 270 citations in OpenAlex.
- Whole-body imaging for distant staging of bone chondrosarcoma: a systematic review.La Radiologia medica · 2025Pooled it
- A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma.Current oncology (Toronto, Ont.) · 2024Pooled it
- Clinicopathological and prognostic value of hypoxia-inducible factor-1α in patients with bone tumor: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2019Pooled it
- Trial
- Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.Cancer treatment reviews · 2026Review
- Molecular Pathogenesis, Tumor Microenvironment and Health Disparities in Select Pediatric Solid Tumors: An Integrative Narrative Review.Diseases (Basel, Switzerland) · 2026Review
- Skeletal stem cell lineages in osteosarcoma and bone metastasis.Journal of bone and mineral metabolism · 2026Review
- Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.International journal of molecular sciences · 2026Article
- Molecular and Immune Mechanisms Governing Cancer Metastasis, Including Dormancy, Microenvironmental Niches, and Tumor-Specific Programs.International journal of molecular sciences · 2026Review
- A novel tool to predict the probability of pulmonary metastasis in patients with primary osseous sacral/pelvic tumors: a large real-world multicenter study.BMC pulmonary medicine · 2025Article
- Monomelic, Multicentric, Metachronous Primary Chondrosarcoma of the Lower Limb: A Case Report.Cureus · 2025Article
- Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine.Cancers · 2025Review
- PTPN11 in cartilage development, adult homeostasis, and diseases.Bone research · 2025Review
- A rare case of rib chondrosarcoma with purely mesenchymal cells metastases to thyroid.Diagnostic pathology · 2025Review
- Mesenchymal Stem Cells-Derived Small Extracellular Vesicles and Their Validation as a Promising Treatment for Chondrosarcoma in a 3D Model in Vitro.Biotechnology and bioengineering · 2025Article
- Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature.Current issues in molecular biology · 2024Review
- A single-cell atlas of conventional central chondrosarcoma reveals the role of endoplasmic reticulum stress in malignant transformation.Communications biology · 2024Article
- Hedgehog activation promotes osteogenic fates of growth plate resting zone chondrocytes through transient clonal competency.JCI insight · 2024Article
- Decoupling NADCell reports. Medicine · 2024Article
- Global research development of chondrosarcoma from 2003 to 2022: a bibliometric analysis.Frontiers in pharmacology · 2024Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a group, cartilage tumours are the most common primary bone lesions. They range from benign lesions, such as enchondromas and osteochondromas, to malignant chondrosarcoma. The benign lesions result from the deregulation of the hedgehog signalling pathway, which is involved in normal bone development. These lesions can be the precursors of malignant chondrosarcomas, which are notoriously resistant to conventional chemotherapy and radiotherapy. Cytogenetic studies and mouse models are beginning to identify genes and signalling pathways that have roles in tumour progression, such as hedgehog, p53, insulin-like growth factor, cyclin-dependent kinase 4, hypoxia-inducible factor, matrix metalloproteinases, SRC and AKT, suggesting potential new therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.